Proteomics

Dataset Information

0

Serum proteomics of T2DM individuals with HFpEF after dapagliflozin treatment by tandem mass spectrometry


ABSTRACT: A quantitative proteomic profiling by TMT was performed on serum of T2DM individuals with or without dapagliflozin treatment

ORGANISM(S): Homo Sapiens

SUBMITTER: Bin Feng  

PROVIDER: PXD037538 | iProX | Tue Oct 18 00:00:00 BST 2022

REPOSITORIES: iProX

altmetric image

Publications

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes.

Feng Bin B   Yu Peiran P   Yu Hao H   Qian Buyun B   Li Yuan Y   Sun Kangyun K   Shi Bimin B   Zhang Nannan N   Xu Guidong G  

Diabetology & metabolic syndrome 20230629 1


<h4>Background</h4>Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and lacks effective treatment. We investigated the protective effects of the long-term application of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin on diabetes-associated HFpEF in a rat model. Serum proteomics and metabolomics analysis were also conducted in type 2 diabetic patients with HFpEF treated with dapagliflozin.<h4>Methods</h4>Male Zucker diabetic fatty  ...[more]

Similar Datasets

| PRJNA1220304 | ENA
2023-11-11 | GSE217975 | GEO
2022-04-13 | GSE185845 | GEO
2020-08-28 | GSE156993 | GEO
2025-06-04 | GSE298690 | GEO
2010-11-29 | GSE19420 | GEO
2010-05-16 | E-GEOD-15790 | biostudies-arrayexpress
| PRJNA1238196 | ENA
2013-04-11 | GSE37177 | GEO
2013-04-11 | E-GEOD-37177 | biostudies-arrayexpress